Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug Administration (FDA) on Monday approved the immunotherapy Jemperli (dostarlimab-gxly) for certain adults with rectal cancer that hasn't been treated yet.